【摘要】 目的　探讨利培酮治疗首发精神分裂症的长期效果。方法　对 87例利培酮治疗出院的首发精神分裂症患者进行为期 3年随访 ,以总体印象量表 ( CGI)、副反应量表 ( TESS)及社会功能缺陷量表 ( SDSS)评估利培酮治疗的社会功能恢复状况 ,临床疗效及药物副反应等 ,并与同期氯氮平治疗的首发精神分裂症患者 87例进行对照。结果　利培酮组 CGI得分中EI:1 .88± 0 .81较氯氮平组 1 .48± 0 .5 1显著性增高 ( P<0 .0 5 )。利培酮组与氯氮平组 SDSS评分分别为 3 .2 2± 2 .5 6和5 .5 3± 2 .5 1具有显著性差异 ( P<0 .0 0 1 )。TESS结果显示两组差异并不显著 ,但是副反应表现不同。利培酮与氯氮平治疗首发精神分裂症病人 ,3年内复发率分别为 1 1 .49%和 3 1 .0 3 % ,( P<0 .0 0 1 ) ,再住院率分别为 9.2 0 %和 45 .98% ( P<0 .0 1 ) ,均具有显著性差异。结论　两种药物治疗出院的首发精神分裂症患者 ,以长期疗效、社会功能的恢复及预后利培酮组优于氯氮平组 ,因此首发精神分裂症患者应首选利培酮更多还原

【Abstract】 Objective To explore the long-term effect of risperidone in the treatment first-onset schizophrenia.Methods A 3-year follow-up study was done to 87 cases of schizophrenia,who were first-onset and discharged.The Clinical Global Impressions scale(CGI),the Treatment Emergent Symptoms Scale(TESS) and Social Disability Screening Schedule(SDSS) were used to evaluate social function,effectiveness and side effects.87 cases were as controls.Results The CGI score in study group was higher than control group(1.88±0.81 vs 1.48±0.51,P<0.05).SDSS scores in study group and control group were 3.22±2.56 and 5.53±2.51,respectively.There was significant differences between the two groups(P<0.001),The relape rate in study group and control group were 11.49% and 31.03% respectively.The rehospitalization rates in study group were 9.20% and 45.98%.respectively.There were a significant differences between the two group(P<0.01).Conclusion Risperidone was better than clozapine in long-term effects,social function and prognosis for schizophrenia.It is suggested to use resperidone firstly for first-onset schizophrenia.更多还原